About Careers MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

U-M Study Finds New Class of Cancer Drugs Could Work in Colon Cancers With Genetic Mutation

by Kathy Jones on April 26, 2011 at 8:46 PM
Font : A-A+

 U-M Study Finds New Class of Cancer Drugs Could Work in Colon Cancers With Genetic Mutation

A new study from the University of Michigan Comprehensive Cancer Center finds that a class of drugs that shows promise in breast and ovarian cancers with BRCA gene mutations could potentially benefit colorectal cancer patients with a different genetic mutation.

Working in cell lines from colorectal cancer patients, researchers found that a new class of drugs called PARP inhibitors worked against tumors with mutations in the MRE11 gene.

Advertisement

About 15 percent of all colorectal cancers have what's called microsatellite instability, a type of error in the DNA. About 82 percent of those tumors have the MRE11 gene mutation.

"This is a potential broader application for PARP inhibitors, beyond breast and ovarian cancer. This is a class of drug that's already shown safety in early clinical trials and now might benefit some colorectal cancer patients as well," says lead study author Eduardo Vilar-Sanchez, M.D., Ph.D., a hematology/oncology fellow at the U-M Medical School.
Advertisement

The study, which was published in Cancer Research, also found that PARP inhibitors are even more effective when both copies of MRE11 were mutated. Each person carries two copies of each gene, which means mutations can occur in either one or both copies. The researchers suggest that PARP inhibitors could be targeted specifically to colorectal cancer patients who have two copies of the mutated gene.

Researchers are planning a phase I clinical trial to look at using PARP inhibitors in colorectal cancer patients with two mutated copies of MRE11. Future trials are being considered using PARP inhibitors to prevent colorectal cancer and other cancers in people with Lynch syndrome whose tumors have this mutation.

Microsatellite instability is also seen in prostate cancer and endometrial cancer, suggesting potential for PARP inhibitors to play a role in additional types of cancer as well, Vilar-Sanchez says, adding that more research is needed in these areas.



Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Diet and Oral Health: The Sugary Connection May Become Sour
World AIDS Day 2022 - Equalize!
Test Your Knowledge on Sugar Intake and Oral Health
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drug Toxicity Cancer and Homeopathy Genetics and Stem Cells Colo-rectal cancer - Management Colorectal Cancer Cancer Facts Cancer Tattoos A Body Art Colon Crohns Disease 

Most Popular on Medindia

Blood Donation - Recipients Diaphragmatic Hernia Calculate Ideal Weight for Infants A-Z Drug Brands in India Accident and Trauma Care Hearing Loss Calculator Blood - Sugar Chart Indian Medical Journals Noscaphene (Noscapine) Sanatogen
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
×

U-M Study Finds New Class of Cancer Drugs Could Work in Colon Cancers With Genetic Mutation Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests